7210 Wareham Drive, Tampa, FL 33647
Feb. 25, 2025 Eli Lilly said today that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from cheap, compounded copies of weight loss medications. Zepbound was originally sold in injectable pens at […]
Eli Lilly To Lower Price of Zepbound Vials, GLP-1 Shortage Is Over Read More »
Feb. 2o, 2025 Herbalife reported Q4 and full year 2024 results. The company sells a significant amount of weight loss and meal replacement products each year. “With three consecutive quarters of new distributor growth, a new incoming CEO and significantly improved Adjusted EBITDA2 margins, we enter 2025 with strong momentum.” – Michael Johnson, Chairman and
Herbalife Reports 2024 Results, $567 Million Weight Loss U.S. Sales Read More »
Feb. 18, 2025 “This past year was a pivotal year for Medifast, as we continued to transform our business to meet the changing nature of a health and wellness market that has been revolutionized by the rising acceptance of GLP-1 medications,” said Dan Chard, Chairman & CEO. Fourth quarter 2024 revenue decreased 37.7% to $119.0
Medifast Reports Q4 and Full Year 2024 Results Read More »
Feb. 3, 2025 Support for the wildly popular weight loss meds in the new administration appears to be a question mark. Dr. Oz has publicly praised GLP-1s for their benefits, even pitching them on TV and social media channels, according to a Dec. 30 report from The Hill. On the other hand, Mr. Kennedy expressed
Conflicts in Trump Administration For Support of GLP-1 Meds Read More »
January 27, 2025 Shortages is that they don’t last forever, and that applies to compounded weight loss meds. After some legal wrangling, the FDA pulled tirzepatide from its shortage list in December, giving compounders a short grace period to wrap things up. That means people taking the copycats will soon need to switch to the
The Party Is Almost Over for GLP-1 Compounders Read More »
Dec. 20, 2024 The Food and Drug Administration said that a nationwide shortage of Eli Lilly’s Zepbound and Mounjaro has been resolved, eliminating the need for copycat versions of the drugs that have become wildly popular with Americans trying to lose weight. Zepbound is FDA-approved to treat obesity and Mounjaro is approved for diabetes. They
FDA Says Shortage Is Over, Compounders Have 60-90 Days Read More »
Dec. 4, 2024 StatNews.com today reported that…. Eli Lilly’s drug Zepbound resulted in weight loss that was 47% greater than the weight loss achieved with Wegovy, the rival medicine made by Novo Nordisk, according to a new head-to-head study out this morning. The news likely will not be entirely surprising to the physicians and scientists
Zepbound Beats Wegovy for Weight Loss Read More »
November 20, 2024 Herbalife’s sales of weight management products in North America continue to decline, most likely due to strong competition from the GLP-1 weight loss drugs. Total U.S. sales for the 9 months ended Sept. 30, 2024 were down 7.9%, and North American sales represented 21% of the total. Total weight management sales from
Herbalife Weight Management Sales Continue Slide Read More »
Nov. 6, 2024 WW (Weight Watchers) reported results for the 3rd quarter 2024 today. “For over six decades, Weight Watchers has been the trusted leader in weight management, offering a full spectrum of science-backed, proven weight management solutions. With our expanded clinical offering, iconic trusted brand, and global community of members, we are well-equipped to
Weight Watchers Reports 3rd Quarter Results Read More »
Nov. 4, 2024 Medifast reported Q3 results today. CEO Dan Chard said: “With tailored plans, personal solutions and a focused approach to driving customer acquisition, we believe that our strategy can drive sustainable growth in the quarters and years ahead.” Third Quarter 2024 Revenue of $140.2 million, with revenue per active earning coach of $4,672
Medifast Reports 3rd Quarter Results Read More »